Abstract
Methods: A soluble form of E2 protein (sE2) derived from the HCV/Con1 strain was produced at high levels, up to 100mg/L, in stably transfected Drosophila S2 cell culture. This sE2 protein could bind to HCV receptors CD81 and SRB1, block cell-culture-derived HCV (HCVcc) infection, and react with known broadly neutralising monoclonal antibodies. Findings: Immunisation studies showed that sE2 was able to induce production of serum antibodies neutralising HCVcc of all seven genotypes in mice, rabbits, and rhesus macaques. Additionally, sE2-immunised macaques developed systemic and intra-hepatic memory T cells specific for E2. In-vivo challenge and protection studies are ongoing to determinewhether such neutralisation is sufficient to prevent HCV infection in mice. Interpretation: These data show that sE2 is a promising HCV vaccine candidate that warrants further preclinical and clinical development.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.